|Bid||14.900 x 1100|
|Ask||15.000 x 1200|
|Day's Range||14.900 - 15.275|
|52 Week Range||11.900 - 20.300|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) as an investment opportunity. Anyone interestedRead More...
Vanda officials said they were able to show Hetlioz, their drug approved in the U.S. and Europe for a circadian rhythm condition known as non-24 sleep-wake disorder, showed "meaningful benefits" in addressing the symptoms of jet lag disorder . "Hetlioz improved both nighttime sleep and daytime alertness, potentially offering benefits to millions of travelers," said Dr. Mihael Polymeropoulos, CEO of Vanda, in a conference call with analysts on Monday. The trial results didn't move Vanda's stock very much Monday afternoon — it gained 30 cents, or 1.6 percent, to close at $19.30 per share on average trading volume — but that may be because of the additional challenges facing the company to get federal approval and market penetration for a jet lag disorder drug.
Headquartered in Dublin, Ireland, Alkermes (ALKS) is an integrated biopharmaceutical company engaged in the research, development, and commercialization of pharmaceutical products. Of the 12 analysts covering Alkermes (ALKS) in February 2018, five analysts gave the stock a “buy” or a higher rating.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018.
The increase was due to an expansion of the Fanapt sales force and marketing efforts by Vanda Pharmaceuticals for Fanapt and Hetlioz. Total operating expenses incurred by Vanda Pharmaceuticals were $181.9 million in fiscal 2017 compared with $164.5 million in fiscal 2016. In the next part of this series, we’ll look at the key events to watch in Vanda Pharmaceuticals’ product pipeline.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company.
Categories: Yahoo FinanceGet free summary analysis Vanda Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Vanda Pharmaceuticals, Inc. – Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pernix Therapeutics Holdings, Inc. ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vanda Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to VNDA-US. Comparing the performance and risk of Vanda Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Vanda Pharmaceuticals Inc (NASDAQ:VNDA), a pharmaceuticals, biotechnology and life sciences company based in United States, View our latest analysis for Vanda Pharmaceuticals What is VNDA worth? According to my valuationRead More...
Vanda Pharmaceuticals (VNDA) stock is looking quite impressive now for momentum-oriented investors.
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
Companies with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Vanda Pharmaceuticals, Inc. a score of 41. Our analysis is based on comparing Vanda Pharmaceuticals, Inc. with the following peers – Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Pernix Therapeutics Holdings, ... Read more (Read more...)